|
|
Volumn 13, Issue 4, 2012, Pages 319-
|
|
Biology-driven medicine: Tissue matters
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
GEFITINIB;
IMATINIB;
IPILIMUMAB;
MAMMALIAN TARGET OF RAPAMYCIN;
PHOSPHATIDYLINOSITOL 3 KINASE;
VEMURAFENIB;
BIOMEDICINE;
BIOPSY;
CANCER TISSUE;
CHRONIC MYELOID LEUKEMIA;
EDITORIAL;
GENE MUTATION;
GENETIC HETEROGENEITY;
GENETIC SCREENING;
HISTOLOGY;
HUMAN;
LUNG NON SMALL CELL CANCER;
MELANOMA;
MOLECULARLY TARGETED THERAPY;
PATIENT SELECTION;
PERSONALIZED MEDICINE;
PRIORITY JOURNAL;
TREATMENT RESPONSE;
DRUG RESISTANCE, NEOPLASM;
GENETIC HETEROGENEITY;
HUMANS;
INDIVIDUALIZED MEDICINE;
MUTATION;
NEOPLASMS;
TRANSLATIONAL MEDICAL RESEARCH;
|
|
EID: 84859117717
PISSN: 14702045
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/S1470-2045(12)70142-0 Document Type: Editorial |
|
Times cited : (1)
|
|
References (0)
|